ReviewCurrent rheumatology reports2004
Gene therapies for osteoarthritis.
Review in Current rheumatology reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The role of FoxO3a in the pathogenesis of osteoarthritis and its therapeutic applications.Frontiers in immunology · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment.Materials today. Bio · 2022Review
- Gene therapy approaches for equine osteoarthritis.Frontiers in veterinary science · 2022Review
- Inhibition of vascular endothelial growth factor with shRNA in chondrocytes ameliorates osteoarthritis.Journal of molecular medicine (Berlin, Germany) · 2016Article
- Tissue-engineering strategies to repair joint tissue in osteoarthritis: nonviral gene-transfer approaches.Current rheumatology reports · 2014Review
- The effect of local anaesthetics on synoviocytes: a possible indirect mechanism of chondrolysis.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2013Article
- RNA therapeutics targeting osteoclast-mediated excessive bone resorption.Advanced drug delivery reviews · 2012Review
- Stem cells and gene therapy for cartilage repair.Stem cells international · 2012Article
- Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors.Human gene therapy · 2009Article
- Orthopedic gene therapy in 2008.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations.Gene therapy · 2006Article
- Dose-dependent improvements in outcome with adenoviral expression of interleukin-10 in a murine model of multisystem organ failure.Gene therapy · 2006Article
- Disease-modifying therapies for osteoarthritis : current status.Drugs & aging · 2005Review
- Osteoarthritis gene therapy.Gene therapy · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a major health problem in urgent need of better treatment. Gene therapy offers to meet this need. Of the different strategies for using gene therapy in OA, local gene transfer to synovium is in the most advanced stage of development. Local gene transfer brings several advantages, including a focused, local therapy that promises greater efficacy with reduced side-effects, potentially at far lower cost. Moreover, its clinical feasibility has already been confirmed in two Phase I studies of gene therapy for rheumatoid arthritis. Although there are numerous candidate genes of potential use in treating OA genetically, considerable evidence identifies interleukin-1 (IL-1) as a key target. The existence of a natural antagonist, the IL-1 receptor antagonist (IL-1Ra), provides a means with which to inhibit its biologic actions. Clinical studies are suggested in which IL-1Ra complementary DNA is transferred to knee joints shortly before they are surgically replaced with prostheses. This will permit the ready assessment of the safety and efficiency of gene transfer and expression in the human OA knee, as well as permitting preliminary functional data to be obtained, as a prelude to phase II efficacy studies. At this point, the major barriers to progress are financial rather than intellectual or technical.
Indexed as
Identifiers
14713400What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.